Dyne Therapeutics, Inc.

DYN

Dyne Therapeutics, Inc.

DYN

Insider Sentiment (TTM):

Last Purchase:2026-06-08Last Sale:2026-06-29Shares Purchased (TTM):16,000Shares Sold (TTM):1,927,670

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:150,782,447Shares Outstanding:165,201,329Institutional Ownership Pct.:91.27%

Earnings Market Reaction:

Filing Date:2026-07-29Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	676	753	893	574	485	472	435	532	608	272	122	130
Assets Current
Assets Current	938	1,021	1,127	806	698	690	659	736	792	488	129	168
Available For Sale Securities Debt Securities Curr…	222	219	217	218	199	205	207	192	171	182	1	28
Prepaid Expense And Other Assets Current	39	49	16	14	14	12	17	13	13	35	6	10
Property Plant And Equipment Net	25	24	24	24	6	6	5	5	5	5	5	5
Operating Lease Right Of Use Asset	20	20	21	22	23	24	25	26	27	28	29	30
Assets	994	1,080	1,187	867	729	721	691	769	826	522	165	205
Liabilities And Stockhold…
Liabilities
Accounts Payable Current	12	11	8	12	14	7	7	6	2	7	23	4
Accrued Liabilities And Other Liabilities	46	29	38	43	22	22	31	32	23	10	23	21
Liabilities Current
Liabilities Current	78	51	51	60	41	34	42	43	30	22	51	30
Operating Lease Liability Current	5	5	5	5	5	5	5	5	5	5	5	5
Long Term Debt	199	149	149	99	99	-	0	-	-	-	-	-
Operating Lease Liability Noncurrent	15	14	15	16	17	18	19	20	21	22	23	24
Liabilities	292	215	215	175	158	52	61	63	51	44	74	53
Preferred Stock Value	0	-	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Additional Paid In Capital	2,398	2,382	2,368	1,975	1,747	1,734	1,580	1,565	1,539	1,176	724	718
Stockholders Equity	702	865	972	692	571	669	630	706	775	478	91	152
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	0	0	0	0	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-1,696	-1,517	-1,396	-1,284	-1,176	-1,065	-950	-860	-763	-698	-633	-566
Liabilities And Stockholders Equity	994	1,080	1,187	867	729	721	691	769	826	522	165	205
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	400	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	166	165	165	143	114	114	102	102	100	87	61	61
Shares Outstanding	166	165	165	143	114	114	102	102	100	87	61	61

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-7.69%	24.97%	36.40%	-	-	-	-	-	-	-	-	-
2025	5.89%	-15.27%	-11.91%	35.12%	41.03%	75.94%	4.78%	-4.11%	-13.88%	6.13%	13.07%	7.55%
2024	20.08%	34.69%	59.50%	-23.31%	-24.36%	-33.27%	0.58%	-15.58%	-51.52%	-8.28%	-37.97%	-10.17%
2023	-	-	-	3.39%	-20.96%	-36.96%	50.96%	72.81%	113.39%	9.74%	-4.41%	20.68%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	12.02	19.92	22.25	13.47	16.83	20.35	15.60	17.02	26.63	21.83	2.53	5.67
Quick Ratio	11.51	18.97	21.94	13.23	16.49	20.00	15.20	16.73	26.18	20.28	2.41	5.32
Working Capital	859.86M	969.78M	1.08B	746.41M	656.48M	655.62M	617.02M	693.13M	762.57M	465.78M	78.28M	138.52M
Leverage & Debt
Debt to Equity	0.42	0.25	0.22	0.25	0.28	0.08	0.10	0.09	0.07	0.09	0.81	0.35
Debt Ratio	0.29	0.20	0.18	0.20	0.22	0.07	0.09	0.08	0.06	0.08	0.45	0.26
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Free Cash Flow Per Share TTM	-2.90	-2.68	-2.46	-2.65	-3.17	-2.84	-2.88	-2.40	-2.20	-2.53	-3.07	-2.99
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	25.80%	23.04%	40.58%	43.90%	60.28%	42.63%	34.54%	41.51%	36.08%	45.67%	40.36%	14.95%
EPS Growth (1Y)	-13.18%	-15.37%	-12.80%	2.67%	40.35%	9.31%	-19.18%	-14.72%	-17.07%	-2.48%	27.04%	-2.70%
Valuation Metrics
P/E TTM	-7.08	-6.63	-7.23	-4.26	-2.64	-3.24	-7.59	-12.41	-13.72	-9.61	-3.47	-2.64
P/B TTM	5.24	3.46	3.32	2.61	1.90	1.78	3.83	5.18	4.56	5.17	8.96	3.61
Market Cap	3.68B	3.00B	3.23B	1.80B	1.09B	1.19B	2.41B	3.65B	3.53B	2.47B	817.53M	549.45M
Enterprise Value	3.20B	2.39B	2.48B	1.33B	702.28M	716.35M	1.98B	3.12B	2.93B	2.20B	695.91M	419.17M
Calculated Values
Free Cash Flow TTM	-480.43M	-443.40M	-405.13M	-378.22M	-361.93M	-322.89M	-294.75M	-244.42M	-220.31M	-220.48M	-188.89M	-183.51M
Net Debt	-476.79M	-603.73M	-744.45M	-474.46M	-386.23M	-472.26M	-435.45M	-532.16M	-608.20M	-272.04M	-121.63M	-130.28M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-29Sale

Owner: Rhodes, Jason P

Title: -

Shares: 195,427

Price/Share: $21.14

Value: $4,131,326.78

Shares Owned: 975,931

Relationship: Director

Ownership: Indirect

2026-06-25Sale

Owner: Lucera, Erick

Title: Chief Financial Officer

Shares: 2,362

Price/Share: $20.37

Value: $48,113.94

Shares Owned: 121,563

Relationship: Officer

Ownership: Direct

2026-06-25Sale

Owner: Rhodes, Jason P

Title: -

Shares: 24,100

Price/Share: $21.10

Value: $508,510.00

Shares Owned: 1,081,044

Relationship: Director

Ownership: Indirect

2026-06-23Sale

Owner: Kersten, Dirk

Title: -

Shares: 73,286

Price/Share: $21.26

Value: $1,558,060.36

Shares Owned: 3,848,256

Relationship: Director

Ownership: Indirect

2026-06-18Sale

Owner: Kersten, Dirk

Title: -

Shares: 46,901

Price/Share: $20.07

Value: $941,303.07

Shares Owned: 4,112,218

Relationship: Director

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-29	Rhodes, Jason P	Director	-	Indirect	Sale	195,427	21.14	$4,131,326.78	975,931	4
2026-06-25	Lucera, Erick	Officer	Chief Financial Officer	Direct	Sale	2,362	20.37	$48,113.94	121,563	4
2026-06-25	Rhodes, Jason P	Director	-	Indirect	Sale	24,100	21.10	$508,510.00	1,081,044	4
2026-06-23	Kersten, Dirk	Director	-	Indirect	Sale	73,286	21.26	$1,558,060.36	3,848,256	4
2026-06-18	Kersten, Dirk	Director	-	Indirect	Sale	46,901	20.07	$941,303.07	4,112,218	4
2026-06-16	Cox, John	Director,Officer	CEO & President	Direct	Sale	2,683	18.33	$49,179.39	368,151	4
2026-06-16	Friedl-Naderer, Johanna	Officer	Chief Commercial Officer	Direct	Sale	145	18.33	$2,657.85	154,208	4
2026-06-16	Kerr, Douglas	Officer	Chief Medical Officer	Direct	Sale	887	18.33	$16,258.71	169,155	4
2026-06-08	Posner, Brian S	Director	-	Direct	Purchase	2,000	16.94	$33,880.00	24,500	4
2026-06-03	Posner, Brian S	Director	-	Direct	Purchase	2,500	17.48	$43,700.00	22,500	4
2026-05-26	Posner, Brian S	Director	-	Direct	Purchase	2,000	18.21	$36,420.00	20,000	4
2026-05-20	Posner, Brian S	Director	-	Direct	Purchase	2,500	17.12	$42,800.00	18,000	4
2026-05-13	Kerr, Douglas	Officer	Chief Medical Officer	Direct	Sale	1,564	18.36	$28,715.04	170,042	4
2026-05-13	Cox, John	Director,Officer	CEO & President	Direct	Sale	3,311	18.36	$60,789.96	370,834	4
2026-05-13	Lucera, Erick	Officer	Chief Financial Officer	Direct	Sale	1,448	18.36	$26,585.28	123,925	4
2026-05-13	Friedl-Naderer, Johanna	Officer	Chief Commercial Officer	Direct	Sale	228	18.36	$4,186.08	154,353	4
2026-05-06	Rhodes, Jason P	Director	-	Indirect	Sale	83,219	18.18	$1,512,921.42	7,962	4
2026-04-28	Rhodes, Jason P	Director	-	Indirect	Sale	227,337	18.69	$4,248,928.53	8,511	4
2026-04-27	Rhodes, Jason P	Director	-	Indirect	Sale	173,493	18.15	$3,148,897.95	9,682	4
2026-04-22	Kersten, Dirk	Director	-	Indirect	Sale	2,652	20.00	$53,040.00	4,196,573	4
2026-04-22	Rhodes, Jason P	Director	-	Indirect	Sale	287,956	19.68	$5,666,974.08	11,663	4
2026-04-20	Kersten, Dirk	Director	-	Indirect	Sale	125,274	20.07	$2,514,249.18	4,207,525	4
2026-04-16	Kersten, Dirk	Director	-	Indirect	Sale	17,773	20.58	$365,768.34	4,544,773	4
2026-04-01	Lucera, Erick	Officer	Chief Financial Officer	Direct	Sale	5,727	18.64	$106,751.28	125,373	4
2026-03-30	Posner, Brian S	Director	-	Direct	Purchase	2,000	17.08	$34,160.00	15,500	4
2026-03-11	Posner, Brian S	Director	-	Direct	Purchase	2,000	19.35	$38,700.00	13,500	4
2026-03-11	Kersten, Dirk	Director	-	Indirect	Sale	129,672	19.52	$2,531,197.44	4,644,386	4
2026-03-10	Kersten, Dirk	Director	-	Indirect	Sale	511,098	19.11	$9,767,082.78	4,774,058	4
2026-03-06	Posner, Brian S	Director	-	Direct	Purchase	3,000	15.06	$45,180.00	11,500	4
2026-03-05	Kerr, Douglas	Officer	Chief Medical Officer	Direct	Sale	904	14.90	$13,469.60	171,606	4
2026-03-05	Cox, John	Director,Officer	CEO & President	Direct	Sale	2,732	14.90	$40,706.80	374,145	4
2026-03-05	Friedl-Naderer, Johanna	Officer	Chief Commercial Officer	Direct	Sale	148	14.90	$2,205.20	154,581	4
2025-12-05	Friedl-Naderer, Johanna	Officer	Chief Commercial Officer	Direct	Sale	144	20.72	$2,983.68	94,729	4
2025-12-05	Kerr, Douglas	Officer	Chief Medical Officer	Direct	Sale	880	20.72	$18,233.60	87,510	4
2025-12-05	Cox, John	Director,Officer	CEO & President	Direct	Sale	2,662	20.72	$55,156.64	196,877	4
2025-09-05	Kerr, Douglas	Officer	Chief Medical Officer	Direct	Sale	873	13.41	$11,706.93	88,390	4
2025-09-05	Cox, John	Director,Officer	CEO & President	Direct	Sale	2,640	13.41	$35,402.40	199,539	4
2025-09-05	Friedl-Naderer, Johanna	Officer	Chief Commercial Officer	Direct	Sale	144	13.41	$1,931.04	94,873	4
2025-07-14	Cox, John	Director,Officer	CEO & President	Direct	Purchase	100,000	9.11	$911,000.00	242,179	4
2025-06-05	Cox, John	Director,Officer	CEO & President	Direct	Sale	4,060	13.35	$54,201.00	142,179	4
2025-06-05	Kerr, Douglas	Officer	Chief Medical Officer	Direct	Sale	1,342	13.35	$17,915.70	92,815	4
2025-06-05	Friedl-Naderer, Johanna	Officer	Chief Commercial Officer	Direct	Sale	146	13.35	$1,949.10	95,911	4
2025-03-13	Friedl-Naderer, Johanna	Officer	Chief Commercial Officer	Direct	Sale	143	12.12	$1,733.16	96,057	4
2025-03-11	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	1,343	11.38	$15,283.34	122,330	4
2025-03-11	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	2,153	11.38	$24,501.14	195,840	4
2025-03-05	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	1,094	11.83	$12,942.02	197,993	4
2025-03-05	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	917	11.83	$10,848.11	123,673	4
2025-03-05	Cox, John	Director,Officer	CEO & President	Direct	Sale	4,061	11.83	$48,041.63	146,239	4
2025-03-05	Kerr, Douglas	Officer	Chief Medical Officer	Direct	Sale	1,343	11.83	$15,887.69	94,157	4
2025-02-18	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	2,488	13.95	$34,707.60	124,590	4
2025-02-18	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	2,598	13.95	$36,242.10	199,087	4
2024-12-11	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	2,334	28.12	$65,632.08	201,685	4
2024-12-11	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	1,455	28.12	$40,914.60	127,078	4
2024-12-09	Kersten, Dirk	Director	-	Indirect	Sale	34,437	29.18	$1,004,871.66	5,400,545	4
2024-12-05	Kersten, Dirk	Director	-	Indirect	Sale	3,806	29.05	$110,564.30	5,536,657	4
2024-12-03	Kersten, Dirk	Director	-	Indirect	Sale	29,732	29.05	$863,714.60	5,675,502	4
2024-11-18	Incerti, Carlo	Director	-	Direct	Sale	16,500	28.73	$474,045.00	0	4
2024-11-18	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	2,856	28.20	$80,539.20	137,519	4
2024-11-18	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	2,735	28.20	$77,127.00	95,833	4
2024-11-14	Kersten, Dirk	Director	-	Indirect	Sale	8,929	32.82	$293,049.78	5,786,435	4
2024-11-14	Rhodes, Jason P	Director	-	Indirect	Sale	782	33.10	$25,884.20	15,962	4
2024-10-21	Kersten, Dirk	Director	-	Indirect	Sale	121	35.06	$4,242.26	73,104	4
2024-10-17	Kersten, Dirk	Director	-	Indirect	Sale	13,013	35.17	$457,667.21	86,639	4
2024-10-03	Kersten, Dirk	Director	-	Indirect	Sale	5,441	35.13	$191,142.33	123,323	4
2024-10-02	Kersten, Dirk	Director	-	Indirect	Sale	21,518	35.38	$761,306.84	128,764	4
2024-09-30	Kersten, Dirk	Director	-	Indirect	Sale	30,942	35.75	$1,106,176.50	158,705	4
2024-09-26	Kersten, Dirk	Director	-	Indirect	Sale	1,260	35.29	$44,465.40	189,679	4
2024-09-23	Kersten, Dirk	Director	-	Indirect	Sale	40,831	35.76	$1,460,116.56	193,296	4
2024-09-19	Kersten, Dirk	Director	-	Indirect	Sale	78,739	36.08	$2,840,903.12	313,538	4
2024-09-18	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	2,339	34.55	$80,812.45	140,375	4
2024-09-18	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	1,390	34.55	$48,024.50	98,568	4
2024-09-18	High, Susanna Gatti	Officer	Chief Operating Officer	Direct	Sale	8,976	34.41	$308,864.16	131,636	4
2024-09-17	Kersten, Dirk	Director	-	Indirect	Sale	3,272	35.13	$114,945.36	393,831	4
2024-09-11	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	1,468	31.89	$46,814.52	99,958	4
2024-09-11	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	2,161	31.89	$68,914.29	142,714	4
2024-09-11	High, Susanna Gatti	Officer	Chief Operating Officer	Direct	Sale	5,270	31.89	$168,060.30	140,612	4
2024-09-06	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	126,074	32.39	$4,083,536.86	101,426	4
2024-09-05	Kersten, Dirk	Director	-	Indirect	Sale	1,577	35.03	$55,242.31	398,423	4
2024-09-04	Cox, John	Director,Officer	CEO & President	Indirect	Purchase	32,000	32.83	$1,050,560.00	8,000	4
2024-08-30	Kersten, Dirk	Director	-	Indirect	Sale	31,300	45.75	$1,431,975.00	400,000	4
2024-08-29	Kersten, Dirk	Director	-	Indirect	Sale	56,408	45.50	$2,566,564.00	431,300	4
2024-08-27	Kersten, Dirk	Director	-	Indirect	Sale	65,403	44.28	$2,896,044.84	565,561	4
2024-08-23	Kersten, Dirk	Director	-	Indirect	Sale	85,088	46.10	$3,922,556.80	720,461	4
2024-08-20	Kersten, Dirk	Director	-	Indirect	Sale	86,840	46.64	$4,050,217.60	1,036,633	4
2024-08-19	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	2,752	45.50	$125,216.00	111,022	4
2024-08-19	Mcneill, Jonathan	Officer	Chief Business Officer	Direct	Sale	2,705	45.50	$123,077.50	132,106	4
2024-08-19	High, Susanna Gatti	Officer	Chief Operating Officer	Direct	Sale	2,910	45.50	$132,405.00	145,882	4
2024-08-19	Kersten, Dirk	Director	-	Indirect	Sale	126,032	45.90	$5,784,868.80	1,123,473	4
2024-08-19	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	2,636	45.50	$119,938.00	144,875	4
2024-08-19	Farwell, Wildon	Officer	Chief Medical Officer	Direct	Sale	2,321	45.50	$105,605.50	143,222	4
2024-08-15	Kersten, Dirk	Director	-	Indirect	Sale	180,891	45.46	$8,223,304.86	1,372,148	4
2024-08-13	Kersten, Dirk	Director	-	Indirect	Sale	133,985	42.81	$5,735,897.85	1,653,689	4
2024-08-09	Kersten, Dirk	Director	-	Indirect	Sale	92,164	43.34	$3,994,387.76	1,866,166	4/A
2024-06-24	High, Susanna Gatti	Officer	Chief Operating Officer	Direct	Sale	10,213	35.33	$360,825.29	148,792	4/A
2024-06-24	High, Susanna Gatti	Officer	Chief Operating Officer	Direct	Sale	10,163	35.33	$359,058.79	148,792	4
2024-06-12	High, Susanna Gatti	Officer	Chief Operating Officer	Direct	Sale	40,000	33.44	$1,337,600.00	148,792	4
2024-06-11	Mcneill, Jonathan	Officer	Chief Business Officer	Direct	Sale	1,823	31.34	$57,132.82	134,811	4
2024-06-11	High, Susanna Gatti	Officer	Chief Operating Officer	Direct	Sale	5,270	31.23	$164,582.10	148,792	4
2024-06-11	Farwell, Wildon	Officer	Chief Medical Officer	Direct	Sale	2,636	31.27	$82,427.72	145,543	4
2024-06-11	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	1,331	31.34	$41,713.54	113,774	4
2024-06-11	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	2,136	31.34	$66,942.24	147,511	4
2024-05-20	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	30,426	33.36	$1,015,011.36	149,647	4
2024-05-16	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	2,588	28.40	$73,499.20	116,695	4
2024-05-16	Mcneill, Jonathan	Officer	Chief Business Officer	Direct	Sale	2,774	28.40	$78,781.60	136,634	4
2024-05-16	Farwell, Wildon	Officer	Chief Medical Officer	Direct	Sale	2,381	28.40	$67,620.40	148,179	4
2024-05-16	High, Susanna Gatti	Officer	Chief Operating Officer	Direct	Sale	2,738	28.40	$77,759.20	154,062	4
2024-05-16	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	2,705	28.40	$76,822.00	149,647	4
2024-03-12	Farwell, Wildon	Officer	Chief Medical Officer	Direct	Sale	1,030	25.58	$26,347.40	150,560	4
2024-03-11	Mcneill, Jonathan	Officer	Chief Business Officer	Direct	Sale	19,601	25.60	$501,785.60	139,408	4
2024-03-11	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	2,081	25.70	$53,481.70	152,352	4
2024-03-11	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	2,672	25.34	$67,708.48	119,283	4
2024-03-11	Brumm, Joshua T	Director,Officer	CEO & President	Direct	Sale	66,387	25.89	$1,718,759.43	537,998	4
2024-03-11	High, Susanna Gatti	Officer	Chief Operating Officer	Direct	Sale	2,292	25.70	$58,904.40	156,800	4
2024-03-07	Farwell, Wildon	Officer	Chief Medical Officer	Direct	Sale	9,921	26.00	$257,946.00	153,175	4
2024-03-07	Brumm, Joshua T	Director,Officer	CEO & President	Direct	Sale	9,086	25.85	$234,873.10	554,385	4
2024-03-07	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	2,273	25.85	$58,757.05	121,955	4
2024-03-07	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	2,373	25.85	$61,342.05	154,433	4
2024-03-07	Mcneill, Jonathan	Officer	Chief Business Officer	Direct	Sale	2,434	25.85	$62,918.90	141,184	4
2024-03-07	High, Susanna Gatti	Officer	Chief Operating Officer	Direct	Sale	1,591	25.85	$41,127.35	186,291	4
2024-03-01	Atlas, Venture Associates…	TenPercentOwner	-	Direct	Sale	29,435	30.05	$884,521.75	1,458,691	4
2024-03-01	Mcneill, Jonathan	Officer	Chief Business Officer	Direct	Sale	24,260	29.00	$703,540.00	143,618	4
2024-03-01	Brumm, Joshua T	Director,Officer	CEO & President	Direct	Sale	94,480	29.06	$2,745,588.80	563,471	4
2024-03-01	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	9,311	28.44	$264,804.84	124,228	4
2024-03-01	Rhodes, Jason P	Director	-	Indirect	Sale	46,534	30.05	$1,398,346.70	847,388	4
2024-02-28	Rhodes, Jason P	Director	-	Indirect	Sale	190,920	25.04	$4,780,636.80	864,487	4
2024-02-28	Atlas, Venture Associates…	TenPercentOwner	-	Direct	Sale	154,674	25.04	$3,873,036.96	5,698,091	4
2024-02-28	Farwell, Wildon	Officer	Chief Medical Officer	Direct	Sale	407	25.00	$10,175.00	163,096	4
2024-02-23	Atlas, Venture Associates…	TenPercentOwner	-	Direct	Sale	159,542	22.70	$3,621,603.40	6,352,562	4
2024-02-23	Rhodes, Jason P	Director	-	Indirect	Sale	196,928	22.70	$4,470,265.60	920,843	4
2024-02-20	Atlas, Venture Associates…	TenPercentOwner	-	Direct	Sale	169,539	23.06	$3,909,569.34	6,815,965	4
2024-02-20	Rhodes, Jason P	Director	-	Indirect	Sale	169,539	23.06	$3,909,569.34	6,815,965	4
2024-02-12	Farwell, Wildon	Officer	Chief Medical Officer	Direct	Sale	5,493	25.07	$137,709.51	163,503	4
2024-01-26	Farwell, Wildon	Officer	Chief Medical Officer	Direct	Sale	100	25.00	$2,500.00	168,996	4
2024-01-26	Mcneill, Jonathan	Officer	Chief Business Officer	Direct	Sale	20,000	24.83	$496,600.00	143,618	4
2024-01-26	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	13,000	24.34	$316,420.00	124,228	4
2024-01-09	Kersten, Dirk	Director,TenPercentOwner	-	Indirect	Purchase	1,714,285	17.50	$29,999,987.50	6,416,793	4
2024-01-04	Brumm, Joshua T	Officer	CEO & President	Direct	Sale	218,536	18.73	$4,093,179.28	584,971	4
2024-01-04	Mcneill, Jonathan	Officer	Chief Business Officer	Direct	Sale	2,009	18.04	$36,242.36	143,618	4
2024-01-04	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	42,453	18.13	$769,672.89	156,806	4
2024-01-03	Scalzo, Richard William	Officer	SVP, Head of Finance & Admin.	Direct	Sale	13,000	18.81	$244,530.00	124,228	4
2023-12-14	Scalzo, Richard William	Officer	See Remarks	Direct	Sale	2,376	12.02	$28,559.52	124,228	4
2023-12-12	Farwell, Wildon	Officer	Chief Medical Officer	Direct	Sale	978	10.55	$10,317.90	169,096	4
2023-12-11	Scalzo, Richard William	Officer	See Remarks	Direct	Sale	1,380	10.72	$14,793.60	126,604	4
2023-12-11	High, Susanna Gatti	Officer	Chief Operating Officer	Direct	Sale	1,616	10.72	$17,323.52	187,882	4
2023-12-11	Brumm, Joshua T	Director,Officer	See Remarks	Direct	Sale	7,585	10.72	$81,311.20	584,971	4
2023-12-11	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	1,467	10.72	$15,726.24	176,585	4
2023-12-11	Mcneill, Jonathan	Officer	Chief Business Officer	Direct	Sale	1,245	10.72	$13,346.40	155,518	4
2023-12-06	Scalzo, Richard William	Officer	See Remarks	Direct	Sale	1,872	12.01	$22,482.72	127,984	4
2023-11-02	High, Susanna Gatti	Officer	Chief Operating Officer	Direct	Sale	9,939	7.40	$73,548.60	94,605	4
2023-09-18	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	1,436	9.41	$13,512.76	84,334	4
2023-09-18	Scalzo, Richard William	Officer	See Remarks	Direct	Sale	1,290	9.41	$12,138.90	40,795	4
2023-09-18	Brumm, Joshua T	Director,Officer	See Remarks	Direct	Sale	12,032	9.41	$113,221.12	233,679	4
2023-09-18	High, Susanna Gatti	Officer	Chief Operating Officer	Direct	Sale	2,672	9.41	$25,143.52	104,544	4
2023-09-18	Mcneill, Jonathan	Officer	Chief Business Officer	Direct	Sale	1,261	9.41	$11,866.01	60,605	4
2023-09-12	Scalzo, Richard William	Officer	See Remarks	Direct	Sale	1,397	10.41	$14,542.77	42,085	4
2023-09-12	Mcneill, Jonathan	Officer	Chief Business Officer	Direct	Sale	1,266	10.41	$13,179.06	61,866	4
2023-09-12	High, Susanna Gatti	Officer	Chief Operating Officer	Direct	Sale	1,635	10.41	$17,020.35	107,216	4
2023-09-12	Beskrovnaya, Oxana	Officer	Chief Scientific Officer	Direct	Sale	1,484	10.41	$15,448.44	85,770	4
2023-09-12	Farwell, Wildon	Officer	Chief Medical Officer	Direct	Sale	1,707	10.41	$17,769.87	89,250	4
2023-09-12	Brumm, Joshua T	Director,Officer	See Remarks	Direct	Sale	7,672	10.41	$79,865.52	245,711	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

91.27%

Inst. Shares: 150,782,447

Shares Outstanding: 165,201,329

2025-12-31

95.20%

Inst. Shares: 157,028,052

Shares Outstanding: 164,950,540

2025-09-30

105.83%

Inst. Shares: 150,925,158

Shares Outstanding: 142,613,248

2025-06-30

107.84%

Inst. Shares: 123,306,786

Shares Outstanding: 114,338,610

2025-03-31

103.19%

Inst. Shares: 117,261,904

Shares Outstanding: 113,633,782

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	150,782,447	165,201,329	91.27%
2025-12-31	157,028,052	164,950,540	95.20%
2025-09-30	150,925,158	142,613,248	105.83%
2025-06-30	123,306,786	114,338,610	107.84%
2025-03-31	117,261,904	113,633,782	103.19%
2024-12-31	108,694,714	102,318,629	106.23%
2024-09-30	108,855,292	101,753,378	106.98%
2024-06-30	107,808,726	100,119,518	107.68%
2024-03-31	93,854,281	87,089,649	107.77%
2023-12-31	62,145,624	61,468,743	101.10%
2023-09-30	58,359,146	61,322,283	95.17%
2023-06-30	57,712,678	61,013,986	94.59%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Dyne Therapeutics, Inc. (DYN) — SEC Financial Statements & Analysis

Dyne Therapeutics, Inc. (DYN) is a pharmaceutical preparations company, incorporated in DE. Dyne Therapeutics, Inc. trades on Nasdaq as: DYN. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Dyne Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.42x, a Price-to-Book (P/B) ratio of 5.24x (TTM), at a market cap of $3.68B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.42x
P/B TTM: 5.24x
Market Cap: $3.68B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Dyne Therapeutics, Inc. in?

Dyne Therapeutics, Inc. (DYN) operates in the Pharmaceutical Preparations industry.

What is DYN's market cap?

Dyne Therapeutics, Inc. (DYN) has a market capitalization of $3.68B as of 2026-06-30.

What exchange does DYN trade on?

Dyne Therapeutics, Inc. (DYN) trades on the Nasdaq.

Where is Dyne Therapeutics, Inc. incorporated?

Dyne Therapeutics, Inc. is incorporated in DE.